CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas
Lists
Only you see this
Abstract
Our study expanded upon previous studies of CD133 and CD44 expressions in skin tumors, suggesting that CD133, but not CD44, may serve as a novel biomarker for differential diagnosis of BCC, although future studies using a larger number of patients are needed to justify it further.
BibTeX
@inproceedings{bi2022cd,
author = {Yalan Bi and Xiaohua Shi and Dian Chen and Yi Zhao},
title = {{CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas}},
booktitle = {Clinical},
year = {2022},
doi = {10.2147/ccid.s373331},
}Loading related content...